CORE--STEM CELL FACILITY

核心——干细胞设施

• 批准号: 6454194
• 负责人: Alan M Gewirtz
• 金额: $ 27.67万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-12-01 至 2001-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6454194
• 关键词: biomedical facility; biomedical resource; hematopoietic stem cells

In 1998, the Cancer Center Executive Committee agreed to plan the establishment of a Stem Cell Biology Core. This Shared Resource will provide access to high quality murine and human hematopoietic stem and progenitor cells based on investigator requests. Such access is invaluable in facilitating and extending the work of investigators involved in the study of transforming oncogenes, the biologic significance of gene mutations, the utility of new gene therapy delivery vectors and understanding the normal cellular processes of adhesion, signaling and cell development. The Core will also assist Cancer Center members engaged in translational and clinical research by proving the technical expertise needed to evaluated the effects of a given intervention/therapy under study on the hematologic system. Available assays will provide the investigator with the ability to determine: the effects on human hematopoietic stem and progenitor cell growth in culture; immunohistochemical analysis of changes in cell surface protein display; and effects on gene expression using RT-PCR, representational analysis (RDA) and high density DNA membrane arrays. The Stem Cell Biology Core will be directed by ALAN Gewirtz, MD, Professor of Medicine and Pathology and Laboratory Medicine, who is recognized for his expertise in stem cell biology and therapeutics and has several NCI grants (RAID, PO1 and R01). Through his personal research experience as a basic, translational and clinical investigator, Dr. Gewirtz, identified the need for such a core in order to conduct innovative research. This was further reinforced by the experience of senior investigators on a PO1 that had a funded core of this type, which has greatly enhanced the quality and timeliness of the related research. Mariusz Ratajczak, MD, PhD, a long-time collaborator of Dr. Gewirtz, will assume the role of Technical Director of the facility. Together, Drs. Gewirtz and Ratajczak have more than 30 years experience in the isolation and culture of hematopoietic stem cells. Usage by Cancer Center members with peer reviewed funding is expected to be 70% of overall usage and total usage by Cancer Center members is expected to be 90% of overall usage.

1998年，癌症中心执行委员会同意计划建立干细胞生物学核心。该共享资源将根据研究者的要求提供高质量的小鼠和人类造血干细胞和祖细胞。这样的访问是非常宝贵的，在促进和扩展研究人员的工作参与转化癌基因的研究，基因突变的生物学意义，新的基因治疗载体的效用和理解正常的细胞过程的粘附，信号和细胞发育。核心还将通过证明评估研究中给定干预/治疗对血液系统的影响所需的技术专业知识，协助癌症中心成员从事转化和临床研究。可用的分析将为研究者提供确定以下方面的能力：对培养中的人造血干细胞和祖细胞生长的影响;细胞表面蛋白显示变化的免疫组织化学分析;以及使用RT-PCR、代表性分析（RDA）和高密度DNA膜阵列对基因表达的影响。干细胞生物学核心将由医学、病理学和实验室医学教授阿兰·格茨（ALAN Geibritz）博士指导，他因其在干细胞生物学和治疗学方面的专业知识而受到认可，并拥有多项NCI赠款（RAID，PO 1和R 01）。通过他作为基础、转化和临床研究者的个人研究经验，Geobritz博士确定了进行创新研究对这样一个核心的需要。高级调查员在一个有这种类型的资助核心的一级方案组织中的经验进一步加强了这一点，这大大提高了相关研究的质量和及时性。Mariusz Ratajczak，MD，PhD，Geopartz博士的长期合作者，将担任该设施的技术总监。Geobritz博士和Ratajczak博士在造血干细胞的分离和培养方面拥有超过30年的经验。癌症中心成员的使用量预计将占整体使用量的70%，癌症中心成员的总使用量预计将占整体使用量的90%。